Effect of two different doses of solifenacin succinate therapy (5mg, 10mg) for the treatment of ureteral stent (Double J) related symptoms in comparison to placebo
Background and objective: Double-J ureteral stent is widely used in endourologic surgery. However, it might cause some annoying side effects. This study aimed to evaluate the effect of two different doses of solifenacin (5mg, 10mg) on double-J stent-related symptoms after uncomplicated ureteroscopic lithotripsy.
Methods: This study involved 120 patients. A total of 80 patients undergoing double-J ureteral stent insertion after ureteroscopic lithotripsy were involved in this study and provided with solifenacin postoperatively; 40 patients received 5mg and another 40 patients received 10mg. Another 40 age- and sex-matched patients without solifenacin therapy (received placebo) were enrolled as a placebo group. All patients completed the modified-form of the Ureteral Symptom Score Questionnaire to evaluate the lower urinary tract symptoms, hematuria and stent-related body pain two weeks following the operation. The severity of stent-related symptoms was compared between the three groups.
Results: The mean age was 45.4 years in the 5 mg solifenacin group, 48.2 years in the 10 mg solifenacin group, and 46.8 years in the placebo group. Compared to the placebo group, both solifenacin groups had significantly lower total symptom score, urgency, and urge incontinence scores. Solifenacin groups had significantly less urethral, abdominal and flank pain and hematuria scores. There was no statistically significant difference between the two solifenacin groups of 5mg and 10mg. The solifenacin groups versus the placebo group showed significant benefits in lower urinary tract symptoms, hematuria, and stent-related pain in both genders. Ten subjects encountered minor adverse events in solifenacin groups (8 in the 10 mg group and 2 in the 5 mg group), which was mostly dry mouth and constipation.
Conclusion: Postoperative solifenacin was effective and well-tolerated in patients undergoing ureteroscopic lithotripsy and double-J stent indwelling irrespective of genders, particularly for the treatment of stent-related body pain, hematuria and the lower urinary tract symptoms.
Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 2013; 41:247–52.
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003; 169:1065–9.
Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Grande M, Giacometti M, et al. Indwelling ureteral stents and sexual health: a prospective, multivariate analysis. J Urol 2007; 178:229–31.
Damiano R, Autorino R, De Sio M, Cantiello F, Quarto G, Perdona S, et al. Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol 2005; 48:673–8.
Sharma R, Choudhary A, Das RK, Basu S, Dey RK, Gupta R, et al. Can a brief period of double J stenting improve the outcome of extracorporeal shock wave lithotripsy for renal calculi sized 1 to 2 cm? Investig Clin Urol 2017; 58(2):103–8.
Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol 2009; 23:1913–7.
Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008; 22:651–6.
Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo-controlled study. J Urol 2009; 181:170–6.
Nagele U, Kuczyk MA, Horstmann M, Hennenlotter J, Sievert KD, Schilling D, et al. Initial clinical experience with full‐length metal ureteral stents for obstructive ureteral stenosis. World J Urol 2008; 26(3):257–62.
Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero- Schwanhaeuser S, Marshall TS, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT—a double-blind, placebo-controlled trial. Int J Clin Pract 2009; 63:1702–14.
Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 2010; 109:702–8.
Lim KT, Kim YT, Lee TY, Park SY. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 2011; 52:485–8.
Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 2003; 169:1060–4.
Gunlusoy B, Degirmenci T, Arslan M, Kozacyoglu Z, Minareci S, Ayder AR. Is ureteral catheterization necessary after ureteroscopic lithotripsy for uncomplicated upper ureteral stones? J Endourol 2008; 22:1645–8.
Chen YT, Chen J, Wong WY, Yang SS, Hsieh CH, Wang CC. Is ureteral stenting necessary after uncomplicated ureteroscopic lithotripsy? A prospective, randomized controlled trial. J Urol 2002; 167:1977–80.
Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006; 67:35–9.
Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol 2010; 183:598–602.
Clayman M, Uribe C, Eichel L, Gordon Z, McDougall EM, Clayman RV. Comparison of guide wires in urology. Which, when and why? J Urol 2004; 171:2146–50.
Sarkissian C, Korman E, Hendlin K, Monga M. Systematic evaluation of hybrid guidewires: shaft stiffness, lubricity, and tip configuration. Urology 2012; 79:513–7.
Tahir W, Hakeem, A, White A, Irving HC, Lloyd SN, Ahmad, N. Extra‐anatomic stent (EAS) as a salvage procedure for transplant ureteric stricture. Am J Transplantation 2014; 14(8):1927–30.
Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 2010; 183:1892–8.
van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:179–83.
Gotman I. Characteristics of metals used in implants. J Endourol 1997; 11(6):383–9.
Park J, Hong B, Park T, Park HK. Effectiveness of noncontrast computed tomography in evaluation of residual stones after percutaneous nephrolithotomy. J Endourol 2007; 21:684–7.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).